Depomed, Inc. (DEPO) Stock Jumps After Successful Phase 3 Trial of New Drug
Depomed, Inc. stock moved up $1.25 to $5.66 in robust trading today on word of top-line results for Phase 3 clinical trials of its new drug. DM-1796 (gabapentin ER) is a newly formulated, once-daily pain relief drug for postherpetic neuralgia (PHN), a persistent condition caused by nerve damage from having shingles. The drug passed FDA’s baseline observation carried forward (BOCF) methodology, and spiked the pain reduction curve on the Lickert pain scale in a ten-week observation period. Solvay Pharmaceuticals, Inc. has been granted a license for DM-1796 in North American markets. In a statement, president and CEO of Depomed, Carl…